FaR-RMS: Frontline and Relapse Study in RhabdomyoSarcoma Study

Patients diagnosed with rhabdomyosarcoma are treated with chemotherapy, radiotherapy and surgery, but many do not survive. Our United Kingdom and European colleagues have developed a new overarching trial, FaR-RMS study, which includes optimising radiotherapy, testing the latest promising agents, new combinations and analysing the length of therapy. Several research questions are addressed within FaR-RMS and new drugs can be rapidly added. Opening FaR-RMS in Australia gives new hope to all patients battling rhabdomyosarcoma.

Disease Stage: Newly diagnosed, relapsed and progressive

Patient Age Range: All ages

Trial Sponsors:

• International: University of Birmingham
• National: ANZCHOG